Russell V. Luepker
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Russell V. Luepker has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
John R. Finnegan
Division of Epidemiology and Community Health, School of Public Health University of Minnesota Minneapolis Minnesota USA
3 shared publications- Lyn M. Steffen
Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis, Minnesota
3 shared publications Milton Eder
Department of Family Medicine and Community Health University of Minnesota Medical School Minneapolis Minnesota USA
3 shared publicationsSue Duval
Cardiovascular Division and Lillehei Heart Institute University of Minnesota Medical School Minneapolis Minnesota USA
3 shared publications- Sue Duval
Cardiovascular Division, University of Minnesota, Minneapolis, MN, USA
3 shared publications Henry Blackburn
The authors are with the Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis
2 shared publications
Latest Publications
- Open Access
- 19 August 2023
- Published by Wiley in Journal of the American Geriatrics Society
- Vol. 71 (12) , 3927-3929
Aspirin use for primary prevention in older adults
- 19 August 2023
- Published by Wiley in Journal of the American Geriatrics Society
- Vol. 71 (12) , 3927-3929
Open AccessAspirin use for primary prevention in older adults
- Open Access
- 9 May 2022
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 5 (5) , e2211107
Association of a Community Population and Clinic Education Intervention Program With Guideline-Based Aspirin Use for Primary Prevention of Cardiovascular Disease A Nonrandomized Controlled Trial
IMPORTANCE Low-dose aspirin is used for primary prevention of cardiovascular disease in approximately one-third of the US adult population. Overuse and underuse are common and not concordant with guidelines. OBJECTIVE To test a community and clinic education intervention to improve guideline-based aspirin use for the primary prevention of cardiovascular disease. DESIGN, SETTING, AND PARTICIPANTS The Ask About Aspirin project was a nonrandomized controlled trial conducted from, July 1, 2015, to March 31, 2020, using professional education, traditional media, and digital media to improve guideline-based aspirin use. The adult population (aged 45-79 years for men and 55-79 years for women) and primary care clinics in Minnesota were the education targets. The 4 adjacent states were controls. INTERVENTIONS The statewide campaign distributed billboards, newspaper articles and other print material, and radio announcements. An Ask About Aspirin website was heavily promoted. Primary care clinics identified appropriate aspirin candidates, and clinicians received continuing education about aspirin. MAIN OUTCOMES AND MEASURES Guideline-based aspirin use by the target population. RESULTS Cross-sectional random telephone surveys of 8342 men aged 45 to 79 years and women aged 55 to 79 years were conducted at baseline, 2 years, and 4 years after the intervention. Participation was similar between men and women (baseline: 973 [49%] vs 1001 [51%]; year 4: 912 [50%] vs 930 [50%]). Age during the study also was similar (baseline: 64.7 [IQR. 64.4-65.1] years; year 4: 66.2 [IQR, 65.8-66.5] years). A validated questionnaire evaluated aspirin use. The Ask About Aspirin website had more than 1 million visits; 124 primary care clinics with more than 1000 participating clinicians were part of the education program. Small, nonsignificant increases in discussions with clinicians regarding aspirin resulted (baseline: 341 of 1001 [34%]; year 4: 339 of 930 [36%]; P = .27). Overall aspirin use decreased after the release of new US Preventive Services Task Force guidelines in 2016 and 3 aspirin randomized clinical trials in 2018 suggested reduced aspirin use (baseline: 816 of 1974 [41%]; year 4: 629 of 1842 [34%); P < .001). Decreases were also noted from year 2 to year 4 in appropriate use (year 2:597 of 1208 [49%]; year 4: 478 of 1191 [40%]; P < .001) and overuse (year 2:170 of 602 [28%]; year 4: 151 of 651 [23%]; P = .04). There were no significant differences between Minnesota and the control states. CONCLUSIONS AND RELEVANCE In this nonrandomized controlled trial, a multiyear statewide campaign was not associated with increased appropriate aspirin use for cardiovascular disease prevention. Contextual factors during the project, including guideline changes and media controversy following the new trials, undermined study goals. These findings suggest that although education programs using social media for cardiovascular disease prevention can result in millions of hits, the use of this strategy to encourage behavior change is problematic, even with supportive clinical sites.
- 9 May 2022
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 5 (5) , e2211107
Open AccessAssociation of a Community Population and Clinic Education Intervention Program With Guideline-Based Aspirin Use for Primary Prevention of Cardiovascular Disease A Nonrandomized Controlled Trial
IMPORTANCE Low-dose aspirin is used for primary prevention of cardiovascular disease in approximately one-third of the US adult population. Overuse and underuse are common and not concordant with guidelines. OBJECTIVE To test a community and clinic education intervention to improve guideline-based aspirin use for the primary prevention of cardiovascular disease. DESIGN, SETTING, AND PARTICIPANTS The Ask About Aspirin project was a nonrandomized controlled trial conducted from, July 1, 2015, to March 31, 2020, using professional education, traditional media, and digital media to improve guideline-based aspirin use. The adult population (aged 45-79 years for men and 55-79 years for women) and primary care clinics in Minnesota were the education targets. The 4 adjacent states were controls. INTERVENTIONS The statewide campaign distributed billboards, newspaper articles and other print material, and radio announcements. An Ask About Aspirin website was heavily promoted. Primary care clinics identified appropriate aspirin candidates, and clinicians received continuing education about aspirin. MAIN OUTCOMES AND MEASURES Guideline-based aspirin use by the target population. RESULTS Cross-sectional random telephone surveys of 8342 men aged 45 to 79 years and women aged 55 to 79 years were conducted at baseline, 2 years, and 4 years after the intervention. Participation was similar between men and women (baseline: 973 [49%] vs 1001 [51%]; year 4: 912 [50%] vs 930 [50%]). Age during the study also was similar (baseline: 64.7 [IQR. 64.4-65.1] years; year 4: 66.2 [IQR, 65.8-66.5] years). A validated questionnaire evaluated aspirin use. The Ask About Aspirin website had more than 1 million visits; 124 primary care clinics with more than 1000 participating clinicians were part of the education program. Small, nonsignificant increases in discussions with clinicians regarding aspirin resulted (baseline: 341 of 1001 [34%]; year 4: 339 of 930 [36%]; P = .27). Overall aspirin use decreased after the release of new US Preventive Services Task Force guidelines in 2016 and 3 aspirin randomized clinical trials in 2018 suggested reduced aspirin use (baseline: 816 of 1974 [41%]; year 4: 629 of 1842 [34%); P < .001). Decreases were also noted from year 2 to year 4 in appropriate use (year 2:597 of 1208 [49%]; year 4: 478 of 1191 [40%]; P < .001) and overuse (year 2:170 of 602 [28%]; year 4: 151 of 651 [23%]; P = .04). There were no significant differences between Minnesota and the control states. CONCLUSIONS AND RELEVANCE In this nonrandomized controlled trial, a multiyear statewide campaign was not associated with increased appropriate aspirin use for cardiovascular disease prevention. Contextual factors during the project, including guideline changes and media controversy following the new trials, undermined study goals. These findings suggest that although education programs using social media for cardiovascular disease prevention can result in millions of hits, the use of this strategy to encourage behavior change is problematic, even with supportive clinical sites.
- 3 February 2021
- Published by Elsevier in American Journal of Preventive Medicine
- Vol. 60 (4) , 513-519
Aspirin Use and Misuse for the Primary Prevention of Cardiovascular Diseases
- 3 February 2021
- Published by Elsevier in American Journal of Preventive Medicine
- Vol. 60 (4) , 513-519
Aspirin Use and Misuse for the Primary Prevention of Cardiovascular Diseases
- Open Access
- 28 March 2019
- Published by Springer Nature in Trials
- Vol. 20 (1) , 185
Use of a Geographic Information System to create treatment groups for group-randomized community trials: The Minnesota Heart Health Program
Group-randomized trials of communities often rely on the convenience of pre-existing administrative divisions, such as school district boundaries or census entities, to divide the study area into intervention and control sites. However, these boundaries may include substantial heterogeneity between regions, introducing unmeasured confounding variables. This challenge can be addressed by the creation of exchangeable intervention and control territories that are equally weighted by pertinent socio-demographic characteristics. The present study used territory design software as a novel approach to partitioning study areas for The Minnesota Heart Health Program’s “Ask about Aspirin” Initiative. Twenty-four territories were created to be similar in terms of age, sex, and educational attainment, as factors known to modify aspirin use. To promote ease of intervention administration, the shape and spread of the territories were controlled. Means of the variables used in balancing the territories were assessed as well as other factors that were not used in the balancing process. The analysis demonstrated that demographic characteristics did not differ significantly between the intervention and control territories created by the territory design software. The creation of exchangeable territories diminishes geographically based impact on outcomes following community interventions in group-randomized trials. The method used to identify comparable geographical units may be applied to a wide range of population-based health intervention trials. National Institutes of Health (Clinical Trials.gov), Identifier: NCT02607917 . Registered on 16 November 2015.
- 28 March 2019
- Published by Springer Nature in Trials
- Vol. 20 (1) , 185
Open AccessUse of a Geographic Information System to create treatment groups for group-randomized community trials: The Minnesota Heart Health Program
Group-randomized trials of communities often rely on the convenience of pre-existing administrative divisions, such as school district boundaries or census entities, to divide the study area into intervention and control sites. However, these boundaries may include substantial heterogeneity between regions, introducing unmeasured confounding variables. This challenge can be addressed by the creation of exchangeable intervention and control territories that are equally weighted by pertinent socio-demographic characteristics. The present study used territory design software as a novel approach to partitioning study areas for The Minnesota Heart Health Program’s “Ask about Aspirin” Initiative. Twenty-four territories were created to be similar in terms of age, sex, and educational attainment, as factors known to modify aspirin use. To promote ease of intervention administration, the shape and spread of the territories were controlled. Means of the variables used in balancing the territories were assessed as well as other factors that were not used in the balancing process. The analysis demonstrated that demographic characteristics did not differ significantly between the intervention and control territories created by the territory design software. The creation of exchangeable territories diminishes geographically based impact on outcomes following community interventions in group-randomized trials. The method used to identify comparable geographical units may be applied to a wide range of population-based health intervention trials. National Institutes of Health (Clinical Trials.gov), Identifier: NCT02607917 . Registered on 16 November 2015.
- Open Access
- 25 June 2013
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 34 (41) , 3191-3197
International comparison of treatment and long-term outcomes for acute myocardial infarction in the elderly: Minneapolis/St. Paul, MN, USA and Goteborg, Sweden
International studies provide an opportunity to compare treatment approaches and outcomes. The present study compares elderly hospitalized acute myocardial infarction (AMI) patients in Minneapolis/St. Paul, USA (MSP) and Göteborg, Sweden (GB). A population-based sample of hospitalized AMI (ICD-9 410) patients aged ≥75 in MSP and GB in 2001–02 was abstracted by trained nurses. Mortality was ascertained from medical records and death certificates. Demographics, cardiovascular procedures, and prescription medications were compared using sex-specific generalized linear models. Adjusted hazard ratios (HR) were calculated with Cox regression. In MSP 839 (387 men, 452 women) and in GB 564 (275 men, 289 women) patients were identified. Age was similar (men: MSP 83 ± 7, GB 82 ± 5; women: MSP 84 ± 6, GB 84 ± 6) yet MSP patients had more previous cardiovascular comorbidities and procedures (PCI/CABG). Guideline-based medication use was high in both locations. MSP patients were significantly more likely to undergo PCI (men: MSP 33%, GB 7%; women: MSP 30%, GB 7%). Survival at 7.5 years was 27.8% among MSP patients (men: 26.6%, women: 28.8%) and 17.2% among GB patients (men: 17.5%, women: 17.0%). After adjustment for baseline characteristics and guideline-based therapies, survival was higher among MSP men [HR: 0.66, 95% confidence interval (CI): 0.50–0.88] and women (HR: 0.49, 95% CI: 0.36–0.67) compared with GB. In MSP and GB, guideline-based therapy use was high. However, PCI use was markedly higher in MSP. Long-term survival was better among elderly men and women in MSP compared with GB possibly related to greater utilization of PCI.
- 25 June 2013
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 34 (41) , 3191-3197
Open AccessInternational comparison of treatment and long-term outcomes for acute myocardial infarction in the elderly: Minneapolis/St. Paul, MN, USA and Goteborg, Sweden
International studies provide an opportunity to compare treatment approaches and outcomes. The present study compares elderly hospitalized acute myocardial infarction (AMI) patients in Minneapolis/St. Paul, USA (MSP) and Göteborg, Sweden (GB). A population-based sample of hospitalized AMI (ICD-9 410) patients aged ≥75 in MSP and GB in 2001–02 was abstracted by trained nurses. Mortality was ascertained from medical records and death certificates. Demographics, cardiovascular procedures, and prescription medications were compared using sex-specific generalized linear models. Adjusted hazard ratios (HR) were calculated with Cox regression. In MSP 839 (387 men, 452 women) and in GB 564 (275 men, 289 women) patients were identified. Age was similar (men: MSP 83 ± 7, GB 82 ± 5; women: MSP 84 ± 6, GB 84 ± 6) yet MSP patients had more previous cardiovascular comorbidities and procedures (PCI/CABG). Guideline-based medication use was high in both locations. MSP patients were significantly more likely to undergo PCI (men: MSP 33%, GB 7%; women: MSP 30%, GB 7%). Survival at 7.5 years was 27.8% among MSP patients (men: 26.6%, women: 28.8%) and 17.2% among GB patients (men: 17.5%, women: 17.0%). After adjustment for baseline characteristics and guideline-based therapies, survival was higher among MSP men [HR: 0.66, 95% confidence interval (CI): 0.50–0.88] and women (HR: 0.49, 95% CI: 0.36–0.67) compared with GB. In MSP and GB, guideline-based therapy use was high. However, PCI use was markedly higher in MSP. Long-term survival was better among elderly men and women in MSP compared with GB possibly related to greater utilization of PCI.
- 1 April 2012
- Published by American Public Health Association in American Journal of Public Health
- Vol. 102 (4) , 705-713
Trends in Smoking Among Adults From 1980 to 2009: The Minnesota Heart Survey
Objectives. We examined population-based smoking trends in Minnesota between 1980 and 2009. Methods. The Minnesota Heart Survey (MHS) is a population-based, serial, cross-sectional study of cardiovascular risk factor trends among Minneapolis–Saint Paul metropolitan residents. The MHS recently completed its sixth survey (1980–1982 [n = 3799], 1985–1987 [n = 4641], 1990–1992 [n = 5159], 1995–1997 [n = 6690], 2000–2002 [n = 3281], and 2007–2009 [n = 3179]). We used MHS data to examine smoking trends among adults aged 25 to 74 years by means of age-adjusted generalized linear mixed models. Results. Between 1980 and 2009, the prevalence of current smoking decreased from 32.8% to 15.5% for men and from 32.7% to 12.2% for women (P < .001 for each). Greater decreases occurred among those with higher income and those with more education. Among currently smoking men, the number of cigarettes smoked per day decreased from 26.0 in the 1980–1982 survey to 16.0 in the 2007–2009 survey (P < .001). Similar trends were observed among women. Conclusions. Although the prevalence of smoking and cigarette consumption decreased from the 1980–1982 period to the 2007–2009 period, interventions specifically designed for those of lower socioeconomic status are needed.
- 1 April 2012
- Published by American Public Health Association in American Journal of Public Health
- Vol. 102 (4) , 705-713
Trends in Smoking Among Adults From 1980 to 2009: The Minnesota Heart Survey
Objectives. We examined population-based smoking trends in Minnesota between 1980 and 2009. Methods. The Minnesota Heart Survey (MHS) is a population-based, serial, cross-sectional study of cardiovascular risk factor trends among Minneapolis–Saint Paul metropolitan residents. The MHS recently completed its sixth survey (1980–1982 [n = 3799], 1985–1987 [n = 4641], 1990–1992 [n = 5159], 1995–1997 [n = 6690], 2000–2002 [n = 3281], and 2007–2009 [n = 3179]). We used MHS data to examine smoking trends among adults aged 25 to 74 years by means of age-adjusted generalized linear mixed models. Results. Between 1980 and 2009, the prevalence of current smoking decreased from 32.8% to 15.5% for men and from 32.7% to 12.2% for women (P < .001 for each). Greater decreases occurred among those with higher income and those with more education. Among currently smoking men, the number of cigarettes smoked per day decreased from 26.0 in the 1980–1982 survey to 16.0 in the 2007–2009 survey (P < .001). Similar trends were observed among women. Conclusions. Although the prevalence of smoking and cigarette consumption decreased from the 1980–1982 period to the 2007–2009 period, interventions specifically designed for those of lower socioeconomic status are needed.
- 18 October 2011
- Published by Wiley in Journal of the American Geriatrics Society
- Vol. 59 (10) , 1970-1971
Population‐Based Smoking Trends in Older Adults: The M innesota Heart Survey
- 18 October 2011
- Published by Wiley in Journal of the American Geriatrics Society
- Vol. 59 (10) , 1970-1971
Population‐Based Smoking Trends in Older Adults: The M innesota Heart Survey
- 1 September 2011
- Published by Elsevier in Journal of the American Dietetic Association
- Vol. 111 (9) , 1329-1334
Trends in Vitamin D Intake from Food Sources among Adults in the Minneapolis-St Paul, MN, Metropolitan Area, 1980-1982 through 2007-2009
- 1 September 2011
- Published by Elsevier in Journal of the American Dietetic Association
- Vol. 111 (9) , 1329-1334
Trends in Vitamin D Intake from Food Sources among Adults in the Minneapolis-St Paul, MN, Metropolitan Area, 1980-1982 through 2007-2009
- 24 September 2008
- Published by Springer Nature in Journal of Cardiovascular Translational Research
- Vol. 1 (4) , 301-304
Minnesota, A Good Place For Your Heart: Trends in Cardiovascular Disease
- 24 September 2008
- Published by Springer Nature in Journal of Cardiovascular Translational Research
- Vol. 1 (4) , 301-304
Minnesota, A Good Place For Your Heart: Trends in Cardiovascular Disease